Johnson & Johnson (JNJ) Goodwill (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Goodwill came in at $48.6 billion in Q1 2026, up 9.2% year-on-year from $44.5 billion in Q1 2025, and little changed quarter-over-quarter from $48.8 billion in Q4 2025.
Johnson & Johnson (JNJ) Goodwill (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Goodwill across 18 years of filings, most recently posting $48.6 billion for Q1 2026.
- Goodwill for Q1 2026 came in at $48.6 billion, up 9.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.6 billion (up 9.2% YoY), and the FY2025 annual result was $48.8 billion, up 10.34% from the prior year.
- Goodwill came in at $48.6 billion for Q1 2026 at Johnson & Johnson, roughly flat from $48.8 billion in the prior quarter.
- In the past five years, Goodwill ranged from a high of $48.8 billion in Q4 2025 to a low of $25.4 billion in Q1 2022.
- The 5-year median for Goodwill is $44.2 billion (2024), against an average of $40.9 billion.
- Peak annual rise in Goodwill reached 17367.5% in 2022, while the deepest fall reached 30.11% in 2022.
- Johnson & Johnson's Goodwill stood at $33.4 billion in 2022, then increased by 9.51% to $36.6 billion in 2023, then climbed by 20.9% to $44.2 billion in 2024, then rose by 10.34% to $48.8 billion in 2025, then fell by 0.44% to $48.6 billion in 2026.
- The last three Goodwill figures came in at $48.6 billion (Q1 2026), $48.8 billion (Q4 2025), and $48.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 48.56 Bn |
| Dec 28, 2025 | 48.77 Bn |
| Sep 28, 2025 | 48.05 Bn |
| Jun 29, 2025 | 48.12 Bn |
| Mar 30, 2025 | 44.47 Bn |
| Dec 29, 2024 | 44.20 Bn |
| Sep 29, 2024 | 44.80 Bn |
| Jun 30, 2024 | 44.25 Bn |
| Mar 31, 2024 | 36.62 Bn |
| Dec 31, 2023 | 36.56 Bn |
| Oct 1, 2023 | 36.12 Bn |
| Jul 2, 2023 | 45.44 Bn |
| Apr 2, 2023 | 45.58 Bn |
| Jan 1, 2023 | 36.05 Bn |
| Oct 2, 2022 | 33.38 Bn |
| Jul 3, 2022 | 34.17 Bn |
| Apr 3, 2022 | 34.94 Bn |
| Jan 2, 2022 | 25.44 Bn |
| Oct 3, 2021 | 35.57 Bn |
| Jul 4, 2021 | 35.82 Bn |